Accordingly, a recent study by Pfister et al. has demonstrated that, in preclinical models of nonalcoholic steatohepatitis (NASH)-induced HCC, the administration of anti-PD-1 agents induced the expansion of intratumoral CD8+ PD1+ T cells, but this phenomenon did not cause tumor regression, suggesting an impairment in the cytotoxic activity of these lymphocytes [204]. The gene discussed is CD8A; the disease is neoplasm.